Elizabeth Sheppard, MBA

Elizabeth Sheppard, MBA

Ms. Sheppard has worked in both private and academic management of Anatomic Pathology laboratories for the past 30 years. Her educational background includes degrees in Histotechnology, Biology and a Masters in Business Administration.

Her faculty experience consists of Clinical Experience Advisor, and Instructor, State University of New York at Cobleskill, Faculty, Wake Forest University School of Medicine, Fundamental of Pathology and Adjunct Faculty at Pima County Community College Histology Program.

Patrick C. Roche, Ph.D.

Patrick C. Roche, Ph.D.

Patrick Roche, PhD is Vice President of Translational Diagnostics at Ventana Medical Systems, Inc. in Tucson, Arizona.  He joined Ventana in August 2002 to lead the Reagent Product Development Team, launching more than thirty In Vitro Diagnostic products, comprising a portfolio of rabbit monoclonal antibodies, an immunohistochemistry panel to evaluate breast cancer, and a series of detection chemistries including enzyme metallography. During his tenure as head of Reagent Development, Dr.

Eric Reiman, MD

Eric Reiman, MD

Dr. Reiman, M.D. is Executive Director of the Banner Alzheimer’s Institute (BAI), Chief Executive Officer for Banner Research, Clinical Director of the Neurogenomics Division at the Translational Genomics Research Institute (TGen), Professor of Psychiatry at the University of Arizona, and Director of the Arizona Alzheimer’s Consortium.

William A. Read, Ph.D.

William A. Read, Ph.D.

William Read oversees the Foundation's basic and translational research programs, and serves as the Foundation's lead official in interfacing with the scientific research community. He also guides the Foundation's interest in emerging grant opportunities in the biomedical research sector and measures to assess the impact of Arizona's investments in the biosciences. Dr. Read is responsible for guiding Foundation programming in biomedical research, medical and graduate medical education, health services research, health policy studies, and the Foundation’s Arts and Culture Program.

John Quackenbush, Ph.D.

John Quackenbush, Ph.D.

John Quackenbush received his Ph.D. in 1990 in theoretical physics from UCLA working on string theory models. Following two years as a postdoctoral fellow in physics, Dr. Quackenbush applied for and received a Special Emphasis Research Career Award from the National Center for Human Genome Research to work on the Human Genome Project. He spent two years at the Salk Institute and two years at Stanford University working at the interface of genomics and computational biology.

Scott D. Patterson, Ph.D.

Scott D. Patterson, Ph.D.

Dr. Patterson is an Executive Director in Medical Sciences at Amgen and has for the past decade been involved in translational research, applying biomarkers for pharmacodynamic assessments and ultimately patient selection. He formed and led the Amgen's successful biomarker program as Molecular Sciences head from 2004-2012 and now heads the Medical Sciences-In Vitro Diagnostic Group, responsible for the transition of biomarkers to IVDs.

David Parkinson, M.D.

David Parkinson, M.D.

David R. Parkinson is a Venture Partner at New Enterprise Associates (NEA). From 2007 until 2012, Dr. Parkinson served as President and CEO of Nodality, a South San Francisco-based biotechnology company focused on the biological characterization of signaling pathways in patients with malignancy to enable more effective therapeutics development and clinical decision-making. Prior to leading Nodality, Dr.

Pages

Subscribe to National Biomarker Development Alliance (NBDA) RSS